7 recruiting, 6 completed, 3 terminated, 2 withdrawn. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Recruiting 7, Completed 6, Terminated 3, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 8 | Completed 2, Recruiting 2, Withdrawn 2, Active not recruiting 1, Terminated 1 |
Follow Vyxeos: new trials by email Literature Review of Vyxeos trials Research Report on Vyxeos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Phase IB/II of CPX-351 for Relapse Prevention in AML CPX-351 - Acute Myeloid Leukemia (AML) in Remission | Phase 1 / Phase 2 | Recruiting | Georgetown University | 24 | 2023-05-22 | 2026-03-23 |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Vyxeos, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2023-02-16 | 2026-02-27 |
| Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Gilteritinib, Vyxeos - Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2022-02-25 | 2025-12-05 |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 1 | 2021-05-21 | 2026-05-20 |
| Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Liposome-encapsulated Daunorubicin-Cytarabine - Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-01-29 | 2026-09-09 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2020-05-27 | 2026-06-02 |
| A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia CPX-351, Venetoclax, Midostaurin - Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 57 | 2019-12-02 | 2023-10-16 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-11-15 | 2020-01-09 | |
| A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML CPX-351, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 35 | 2019-10-15 | 2022-11-09 |
| CPX-351+GO in Subjects 55 Years Old, or Older, With AML CPX-351, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 | Terminated | Weill Medical College of Cornell University | 11 | 2019-08-23 | 2023-03-10 |
| CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myelogenous Leukemia | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 13 | 2019-07-18 | 2023-11-18 |
| Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Palcociclib, CPX-351 - Acute Myeloid Leukemia, AML | Phase 1 / Phase 2 | Completed | Sudipto Mukherjee, MD, PhD, MPH | 35 | 2019-06-06 | 2025-05-31 |
| CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Liposome-encapsulated Daunorubicin-Cytarabine - Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 38 | 2019-05-14 | 2026-10-06 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Vyxeos, Venetoclax - Leukemia | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 21 | 2018-12-27 | 2026-02-18 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 CPX-351 - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 21 | 2018-11-20 | 2021-07-22 |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine Phosphate - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 38 | 2016-05-02 | 2023-09-08 |
Leukemia, Myeloid, Acute (15) · Leukemia (2) · Myelodysplastic Syndromes (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myeloproliferative Disorders (1) · Neoplasm, Residual (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Recurrence (1) · Thrombocythemia, Essential (1)
Jazz Pharmaceuticals (3) · M.D. Anderson Cancer Center (3) · Children's Oncology Group (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Ohio State University Comprehensive Cancer Center (2) · Children's Hospital Medical Center, Cincinnati (1) · Georgetown University (1) · Jonsson Comprehensive Cancer Center (1) · Novartis Pharmaceuticals (1) · Sudipto Mukherjee, MD, PhD, MPH (1) · Thomas Jefferson University (1) · Weill Medical College of Cornell University (1)
United States (17) · Canada (2)
Onyee Chan, MD (2) · Branko Cuglievan (1) · Caspian Oliai, MD (1) · Ellen K Ritchie, MD (1) · Gina Keiffer, MD (1) · Gregory K Behbehani, MD, PhD (1) · Guillermo M Bravo (1) · John Perentesis, MD (1) · Kimberley Doucette, MD (1) · Matthew A Kutny (1) · Musa Yilmaz (1) · Sudipto Mukherjee, MD, PhD (1) · Todd M Cooper (1) · Uma Borate, MD (1)
PMID 33208914, PMID 32401633, PMID 37946611, PMID 38473278, PMID 39418644, PMID 40932876
U10CA180886 (2), 2018 (1)